Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

ASCO 2015: New Information, New Data, and 3rd Party Confirmations

New Information:

Breakdown of Cancer Types

17 gynecological cancers
6 head & neck cancers
5 lung cancers
4 renal /urothelial / bladder cancers
3 skin cancers
2 prostate cancers
2 pancreatic / biliary cancers
1 liposarcoma
Of the 40 Patients:
18 dosed less than or equal to 75 mg/m2
22 dosed greater than or equal to 110 mg/m2
(>100 mg/m2 considered lowest boundary for efficacy)

Clinically Confirmed Biomarker Data:

1. Kevetrin induces cell cycle arrest and apoptosis through activation and stabilization of wild type p53, resulting in increased expression of target genes p21 and PUMA (Kumar 2011).
2. Of the 31 evaluable subjects :
a. 68 % had an increase in p21 expression in a range of 3% to 205%
b. 48 % had an increase in p21 expression of equal to or greater than 10%

Summary New Info and 3rd Party Confirmations:

1. The majority (17 of 40 = plurality? Or, majority of evaluable subjects?) of patients so far are gynecological cancers.
2. Kevetrin shown to activate wild-type p53 and degrade mutant p53
3. Kevetrin activates both transcriptional-dependent and transcriptional-independent pathways to promote apoptosis through wild type p53 activation and degrades oncogenic mutant p53.
4. Kevetrin can function as a major inducer of apoptosis in many types of tumors independent of p53 mutation status.